Apr. 29 at 8:09 PM
Not selling is not a missed opportunity but rather the use of real leverage on
$VKTX's side.
Just giving my input on all of this because I wrote a bunch about VKTX. I wouldn't say not making a deal would be terrible for VKTX, because they do have the market cap and cash to go it alone without destroying shareholder value.
Rather, I think that, since they can go alone, this gives them huge leverage, and the CEO should not sell frantically, but only if the deal is really good.
VKTX is just not in a needy position. Every trial they advance raises the pressure on
$LLY and
$NVO to act, because their drug performs better and may be available for longer (Maintenance Trial). Thus, it's Lilly's or Novo's time to act, not VKTX's.
--> Every trial advancement raises the market cap, thus increasing the premium, and if they reach a point where no one can afford them, they go it alone.
$ABBV